Skip to main content

Advertisement

SpringerLink
Log in

Tumor vaccines in renal cell carcinoma

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Introduction

Although most vaccines target foreign infectious agents, therapeutic cancer vaccines target both well-established and metastatic tumor cells expressing tumor antigens. Active immunotherapy is intended to enhance or activate the immunosurveillance of an individual through a therapeutic vaccine. Renal cell carcinoma (RCC) is one of the most immunoresponsive cancers in humans, which in turn makes it an ideal candidate for immune based therapies.

Method

Several types of therapeutic vaccines have been tested and applied in the clinical setting and can be divided into cell-based vaccines including direct application of inactivated autologous tumor cells, gene modified tumor cell-based, dendritic cell-based (expressing RCC derived tumor antigens), and non-cell-based vaccines. This review will examine the current status of cell-based vaccine immunotherapy and focuses on non-cell-based vaccine strategies.

Conclusion

Recent advances in molecular targeting therapy have introduced a battery receptor tyrosine kinase (RTK) and mTOR inhibitors that provide promising treatment options, however, the tolerability of tumor vaccines and the success of clinical effectiveness in selected populations combined with recent advances in cellular therapies warrant the continued exploration of novel methods of tumor vaccine therapies in the clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ritchie AWS, deKernion JB (1987) The natural history and clinical features of renal carcinoma. Semin Nephrol 7:131–139

    PubMed  CAS  Google Scholar 

  2. Escudier B, Eisen T, Stadler WM, et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  PubMed  CAS  Google Scholar 

  3. Motzer RJ, Huston TE, Tomczak P, et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  4. Tykkä H, Oravisto KJ, Lehtonen T, et al (1978) Active specific immunotherapy of advanced renal-cell carcinoma. Eur Urol 4:250–258

    PubMed  Google Scholar 

  5. Tykkä H (1981) Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study. Scand J Urol Nephrol Suppl 63:1–107

    PubMed  Google Scholar 

  6. Sahasrabudhe DM, deKernion JB, Pontes JE, et al (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod 5:581–594

    PubMed  CAS  Google Scholar 

  7. Fowler JE Jr (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135:22–25

    PubMed  Google Scholar 

  8. Schärfe T, Müller S, Riedmiller H, et al (1989) Immunotherapy of metastasizing renal cell carcinoma. Results of a multicentered trial. Urol Int 44:1–4

    PubMed  Google Scholar 

  9. Kübler H, Vieweg J (2006) Vaccines in renal cell carcinoma. Semin Oncol 33:614–624

    Article  PubMed  Google Scholar 

  10. Ranieri E, Gigante M, Storkus WJ, et al (2007) Translational mini-review series on vaccines: dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 147:395–400

    PubMed  CAS  Google Scholar 

  11. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404–414

    Article  PubMed  CAS  Google Scholar 

  12. Brossart P, Stuhler G, Flad T, et al (1998) Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732–736

    PubMed  CAS  Google Scholar 

  13. Flad T, Spengler B, Kalbacher H, et al (1998) Direct identification of major histocompatibility complex class I-bound tumor-associated peptides antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res 58:5803–5811

    PubMed  CAS  Google Scholar 

  14. Neumann E, Engelsberg A, Decker J, et al (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58:4090–4095

    PubMed  CAS  Google Scholar 

  15. Vissers JL, De Vries IJ, Schreurs MW, et al (1999) The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen(HLA)-A2. 1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59:5554–5559

    PubMed  CAS  Google Scholar 

  16. Tso CL, Zisman A, Pantuck A, et al (2001) Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocytecolony stimulating factor. Cancer Res 61:7925–7933

    PubMed  CAS  Google Scholar 

  17. Uemura H, Fujimoto K, Tanaka M, et al (2006 ) A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12:1768–1775

    Article  PubMed  CAS  Google Scholar 

  18. Iiyama T, Udaka K, Takeda S, et al (2007) WT1 (Wilms’ tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51:519–530

    PubMed  CAS  Google Scholar 

  19. Oki Y, Younes A (2004) Heat shock protein-based cancer vaccines. Expert Rev Vaccines 3:403–411

    Article  PubMed  CAS  Google Scholar 

  20. Guida M, Colucci G. (2007) Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann Oncol 18:149–152

    Article  Google Scholar 

  21. Kurth KH, Marquet R, Zwartendijk J, Warnaar SO. (1987) Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma. Eur Urol 13:103–109

    PubMed  CAS  Google Scholar 

  22. McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 47:1984–1987

    Article  PubMed  CAS  Google Scholar 

  23. Schärfe T, Müller S, Riedmiller H, Jacobi GH, et al (1989) Immunotherapy of metastasizing renal cell carcinoma. Results of a multicentered trial. Urol Int 44:1–4

    Article  PubMed  Google Scholar 

  24. Galligioni E, Quaia M, Merlo A, et al (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette–Guèrin: five-year results of a prospective randomized study. Cancer 77:2560–2566

    Article  PubMed  CAS  Google Scholar 

  25. Schwaab T, Heaney JA, Schned AR, et al (2000) A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 163:1322–1327

    Article  PubMed  CAS  Google Scholar 

  26. Jocham D, Richter A, Hoffmann L, et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599

    Article  PubMed  CAS  Google Scholar 

  27. Kommu S. (2004) Renal-cell carcinoma: vaccination and risk of tumour progression. Lancet 363:1557

    Article  PubMed  Google Scholar 

  28. Frankenberger B, Regn S, Geiger C, et al (2005) Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 23:166–174

    Article  PubMed  CAS  Google Scholar 

  29. Simons JW, Jaffee EM, Weber CE, et al (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537–1546

    PubMed  CAS  Google Scholar 

  30. Antonia SJ, Seigne J, Diaz J, et al (2002) Phase I trial of a B7–1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167:1995–2000

    Article  PubMed  CAS  Google Scholar 

  31. Pizza G, De Vinci C, Lo Conte G, et al (2004) Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol (Praha) 50:175–183

    CAS  Google Scholar 

  32. Amato RJ. (2003) Vaccine therapy for renal cell carcinoma. Rev Urol 5:65–71

    PubMed  Google Scholar 

  33. Avigan D. (2004) Dendritic cell–tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res 10:6347S–6352S

    Article  PubMed  CAS  Google Scholar 

  34. Su Z, Dannull J, Heiser A, et al (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127–2133

    PubMed  CAS  Google Scholar 

  35. Wierecky J, Müller MR, Wirths S, et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66:5910–5918

    Article  PubMed  CAS  Google Scholar 

  36. Kim JH, Lee Y, Bae YS, et al (2007) Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol. doi:10.1016/j.clim.2007.07.014

  37. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al (2007) Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 30:116–122

    Article  PubMed  CAS  Google Scholar 

  38. Matsumoto A, Haraguchi K, Takahashi T, et al (2007) Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol 14:277–283

    Article  PubMed  CAS  Google Scholar 

  39. Avigan DE, Vasir B, George DJ, et al (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30:749–761

    PubMed  Google Scholar 

  40. Date Y, Kimura A, Kato H, et al (1996) DNA typing of the HLA gene population study and identification of four new alleles in Japanese. Tissue Antigens 47:93–101

    Article  PubMed  CAS  Google Scholar 

  41. Wood CG, Escudier B, Gorelov S, et al (2004) A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC). A preliminary report. J Clin Oncol 22: 1925

    Google Scholar 

  42. Brossart P, Heinrich KS, Stuhler G, et al (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309–4317

    PubMed  CAS  Google Scholar 

  43. Achtar MS, Ibrahim RA, Herrin VE, et al (2004) Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma. J Clin Oncol 22:185S

    Google Scholar 

  44. Liao SY, Brewer C, Zavada J, et al (1994) Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145:598–609

    PubMed  CAS  Google Scholar 

  45. Saarnio J, Parkkila S, Parkkila AK, et al (1997) Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153:279–285

    Google Scholar 

  46. Tuner JR, Odze RD, Crum FCP, et al (1997) MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Human Pathol 28:740–744

    Article  Google Scholar 

  47. Swinson DE, Jones JL, Richardson D, et al (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. Clin Oncol 21:473–482

    Article  CAS  Google Scholar 

  48. Shimizu K, Uemura H, Yoshikawa M, et al (2003) Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma. Oncol Rep 10:1307–1311

    PubMed  CAS  Google Scholar 

  49. Dunn GP, Bruce AT, Ikeda H, et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998

    Article  PubMed  CAS  Google Scholar 

  50. Rescigno M, Avogadri F, Curigliano G. (2007) Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 1776:108–123

    PubMed  CAS  Google Scholar 

  51. Parmiani G, Castelli C, Dalerba P, et al (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst 94:805–818

    PubMed  CAS  Google Scholar 

  52. Dillman R, Barth N, Vandermolen L, et al (2004) Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm 19:570–580

    PubMed  CAS  Google Scholar 

  53. Tani K, Azuma M, Nakazaki Y, et al (2004) Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther 10:799–816

    Article  PubMed  CAS  Google Scholar 

  54. Moiseyenko VM, Danilov AO, Baldueva IA, et al (2005) Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. Ann Oncol 16:162–168

    Article  PubMed  CAS  Google Scholar 

  55. Wittig B, Märten A, Dorbic T, et al (2001) Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 12:267–278

    Article  PubMed  CAS  Google Scholar 

  56. Märten A, Renoth S, Heinicke T, et al (2003) Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14:483–494

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan

    Hirotsugu Uemura & Marco A. De Velasco

Authors
  1. Hirotsugu Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco A. De Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirotsugu Uemura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uemura, H., De Velasco, M.A. Tumor vaccines in renal cell carcinoma. World J Urol 26, 147–154 (2008). https://doi.org/10.1007/s00345-008-0246-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-008-0246-3

Keywords

Search

Navigation